NCT00881621 2025-03-03
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Phase 2 Terminated
Clinical Trials
26 trialsNCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00272987 2023-04-28
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Novartis
Phase 3 Terminated
NCT00447122 2022-03-08
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Brown University
Phase 1 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT00508274 2021-09-21
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Novartis
Phase 3 Terminated
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT01264081 2019-11-13
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00759642 2019-07-01
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
University of Kansas Medical Center
Phase 2 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT00225758 2018-07-27
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT01934894 2017-07-02
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01868503 2017-06-26
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Stanford University
Phase 2 Terminated
NCT00496366 2017-03-21
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00490061 2017-03-06
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Stanford University
Phase 2 Terminated
NCT01769508 2016-06-13
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00857714 2015-07-08
Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
Indiana University
Phase NA Terminated
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00709618 2014-07-14
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
GlaxoSmithKline
Phase 2 Terminated
NCT00499681 2012-08-10
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated